These results indicate that HPV-positive status may be a potential biomarker for the application of anti-PD-1/PD-L1 therapy, and HPV-related HNSCC patients could benefit from PD-1 blockade. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.